Skip to main
RZLT

Rezolute (RZLT) Stock Forecast & Price Target

Rezolute (RZLT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rezolute is expected to see strong success in the near future due to their promising results in the ongoing upLIFT study and the potential for a positive outcome from the FDA regarding the regulatory pathway for their drug. The company also has a solid pipeline and partnerships to support their development. With a projected 70% PoS for their program in tumor HI, a potential 2035 revenue of $137M, and a projected PT of $11 based on a 10-year DCF analysis, Rezolute shows strong potential for growth and value creation for investors.

Bears say

Rezolute is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases, including congenital hyperinsulinism. However, their success is dependent on regulatory approvals and the commercialization of their drug candidates. There is potential for competition in the market as well as the need for additional funding, which presents balance sheet risk and could impact the company's profitability.

Rezolute (RZLT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rezolute (RZLT) Forecast

Analysts have given Rezolute (RZLT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Rezolute (RZLT) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rezolute (RZLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.